Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. by Childs, A et al.
Expression of somatostatin receptors 2 and 5
in circulating tumour cells from patients with
neuroendocrine tumours
Alexa Childs1,5, Clare Vesely1,5, Leah Ensell1, Helen Lowe1, Tu Vinh Luong2, Martyn E Caplin3,
Christos Toumpanakis3, Christina Thirlwell1,4, John A Hartley1 and Tim Meyer*,1,4
1UCL Cancer Institute, University College London, London WC1E 6DD, UK; 2Department of Histopathology, Royal Free London
NHS Foundation Trust, London NW3 2QG, UK; 3Department of Gastroenterology, Royal Free London NHS Foundation Trust,
London NW3 2QG, UK and 4Department of Oncology, Royal Free London NHS Foundation Trust, London NW3 2QG, UK
Background: Neuroendocrine tumours (NET) overexpress somatostatin receptors (SSTR) that can be targeted for therapy.
Somatostatin receptor expression is routinely measured by molecular imaging but the resolution is insufficient to define
heterogeneity. We hypothesised that SSTR expression could be measured on circulating tumour cells (CTCs) and used to
investigate heterogeneity of expression and track changes during therapy.
Methods: MCF-7 cells were transfected with SSTR2 or 5 and spiked into donor blood for analysis by CellSearch. Optimum anti-
SSTR antibody concentration and exposure time were determined, and flow cytometry was used to evaluate assay sensitivity. For
clinical evaluation, blood was analysed by CellSearch, and SSTR2/5 immunohistochemistry was performed on matched tissue
samples.
Results: Flow cytometry confirmed CellSearch was sensitive and that detection of SSTR was unaffected by the presence of
somatostatin analogue up to a concentration of 100 ngml l. Thirty-one NET patients were recruited: grade; G1 (29%), G2 (45%),
G3 (13%), primary site; midgut (58%), pancreatic (39%). Overall, 87% had SSTR-positive tumours according to somatostatin
receptor scintigraphy or 68-Ga-DOTATE PET/CT. Circulating tumour cells were detected in 21 out of 31 patients (68%), of which
33% had evidence of heterogeneous expression of either SSTR2 (n¼ 5) or SSTR5 (n¼ 2).
Conclusions: Somatostatin receptors 2 and 5 are detectable on CTCs from NET patients and may be a useful biomarker for
evaluating SSTR-targeted therapies and this is being prospectively evaluated in the Phase IV CALMNET trial (NCT02075606).
Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)
represent a heterogeneous disease entity with diverse biological
and clinical features. They are characterised histologically by
high expression of somatostatin receptors (Yao et al, 2008), of
which five different subtypes have been identified. The most
commonly expressed is SSTR2, followed by SSTR1, SSTR5 and
SSTR3, whereas SSTR4 is the least expressed subtype (de Herder
et al, 2003; Reubi, 2011). This unique expression profile has been
successfully exploited for both diagnostic and therapeutic
applications through the use of somatostatin analogues (SA),
which bind with high affinity to SSTR2 and SSTR5 (Fazio et al,
2010). Somatostatin analogues are commonly used to control
symptoms arising from hormone hypersecretion in functional
NETs, and recent randomised trials have also demonstrated an
anti-proliferative effect resulting in delayed tumour progression
(Rinke et al, 2009; Caplin et al, 2014). Somatostatin receptor
expression has also been investigated as a potential prognostic
factor and SSTR2a but not SSTR5 expression has been shown to be
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an independent positive prognostic factor for survival in pancreatic
NET although prospective validation remains outstanding (Mehta
et al, 2015).
In routine clinical practice, SSTR expression is evaluated by
imaging using scintigraphy or positron emission tomography
(PET) but the resolution of these modalities is insufficient to define
intra-tumoural heterogeneity of SSTR expression, nor is imaging
the optimal method to track changes in expression that may arise
during therapy. We hypothesised that SSTR expression could be
measured on circulating tumour cells (CTCs) and provide insights
into the heterogeneity of expression as well as a means of tracking
expression over time and during therapy. Using the CellSearch
system, we have previously demonstrated that CTCs are detectable
in patients with NET and that their presence is an adverse
prognostic factor (Khan et al, 2011a, 2013b). In addition, we have
shown that early changes in CTC numbers predict survival in
response to therapy (Khan et al, 2015). Here we describe the
development of a CTC-based assay for detecting SSTR expression
and its application in a cohort of GEP NET patients who
have correlative imaging and histological data regarding SSTR
expression.
MATERIALS AND METHODS
Cell lines. In order to develop the assay, we generated EpCAM-
positive cells that expressed either SSTR2 or 5. Human breast
cancer MCF-7 cells were transiently transfected with a mammalian
expression vector carrying full-length human SSTR2 or SSTR5
using GeneJuice reagent (Merck KGaA, Darmstadt, Germany)
according to the transfection reagent kit protocol under the
following optimised conditions; MCF-7 cells were grown to 80%
confluence in MEM medium with 2 M glutamine, 1% non-essential
amino acids and 10% foetal bovine serum (FBS) in 24-well tissue
culture plates at 37 1C and humidified with 5% CO2. Plasmid
pcDNA6.2/hSSTR2 (provided by Ipsen, Slough, UK) was mixed
with the GeneJuice transfection reagent at a ratio of 1.5ml
transfection reagent to 0.5 mg DNA and transfection performed
in complete medium for 48 h prior to trypsinising and freezing at
 80 1C in FBS with 10% DMSO. Transfection efficiency was
assessed by growing cells on glass coverslips and fixing with 4%
paraformaldehyde for 10min. Cells were subsequently permeabi-
lised in phosphate buffered saline (PBS) with 0.5% Tween for
15min and blocked in PBS with 5% bovine serum albumin
(blocking solution) for 30min. Coverslips were then incubated
with 36 mgml 1 anti-SSTR2 Antibody (UMB1, Abcam, Cam-
bridge, UK; ab134152) or 14.8 mgml 1 anti-SSTR5 Antibody
(UMB4, Abcam; ab109495) in blocking solution for 1 h. The
primary antibody was washed off with PBS and the coverslips
incubated with Alexa Fluor 488 Goat Anti-Rabbit IgG (Hþ L)
Antibody A11008 (Life Technologies, Carlsbad, CA, USA) diluted
1 : 200 in blocking solution for a further hour. The secondary
antibody was washed off with PBS and the coverslips mounted on
slides using ProLong Gold Antifade Mountant with DAPI (Life
Technologies, P-36931). Cells were imaged using the Zeiss Axio
M1 microscope to confirm expression of SSTR2 and SSTR5,
respectively.
Detection of SSTR expression using CellSearch. Cells were
spiked into healthy donor blood and analysed using the CellSearch
platform. This semiautomated system enriches for CTCs by
EpCAM targeted immunomagnetic selection, following which
CTCs are identified by positive immunofluorescent staining for
pan-cytokeratin and 4,2-diamidino-2-phenylindole-dihydrochlor-
ide (DAPI), and negative staining for the leucocyte marker CD45.
A fluorescein isothiocyanate-conjugated antibody can be added to
the fourth fluorescence channel to further characterise cells for an
additional marker of interest. For this study, anti-SSTR2 antibody
(UMB1, Abcam; ab134152) and anti-SSTR5 antibody (UMB4,
Abcam; ab109495) were provided as Alexa-488 conjugates by
Abcam. Cells were defined as positive for SSTR expression when
staining was present in the fourth channel. Test runs were
performed for each receptor on the Veridex CellTracks Autoprep
System and CellTracks Analyzer II in order to determine optimal
antibody concentrations and scan time. Three validation runs were
performed using these conditions and spiked healthy donor blood
samples.
Flow cytometry. In order to investigate the sensitivity of SSTR2
and SSTR5 detection using the CellSearch platform, expression
levels were also quantified by flow cytometry for direct
comparison. Transfected MCF-7 cells were prepared as previously
described and harvested using trypsin. Approximately 500 cells
were spiked into healthy donor blood and analysed by CellSearch
as previously described. The remaining cells from the same
harvest were prepared for flow cytometry as follows; cells were
re-suspended in 1ml PBS, centrifuged and re-suspended in 0.5ml
paraformaldehyde prior to incubation at room temperature for
8min. A further centrifugation step was performed before samples
were washed in 1ml PBS and re-suspended in 700 ml PBS for
storage at 4 1C. To evaluate SSTR expression, cells were stained
in triplicate in 96 well plates using 50 mgml 1 SSTR2 (UMB1,
Abcam; ab134152) or 10 mgml 1 SSTR5 (UMB4, Abcam;
ab109495) Alexa-488-conjugated antibodies and analysed using
a BD Fortessa X20 (BD Biosciences, Cambridge, UK). The
percentage of single cells positive for SSTR2 or 5 was then
calculated and compared with that detected using CellSearch.
To establish the effect of SA on the ability to detect SSTR
expression in CTCs, the expression analysis was also performed in
the presence of SA. Transfected MCF-7 cells were treated with
either 0, 10 or 100 ngml 1 lanreotide (BIM-23014; provided by
Ipsen). Untransfected cells were also treated identically and used as
negative control cells. After 16 h overnight incubation, cells were
trypsinised and fixed with 4% paraformaldehyde and stored at
4 1C. Cells were stained in triplicate with 50 mgml 1 SSTR2 or
10 mgml 1 SSTR5 and analysed by BD Fortessa X20 (BD
Biosciences). Between 2000–10 000 events were counted and the
median fluorescent intensity (MFI) was recorded and plotted.
Patients. To be eligible for the study patients were required to
have histologically confirmed NET of midgut or pancreatic origin
or of unknown primary, and metastatic disease measurable by
Response Evaluation Criteria in Solid Tumours (RECIST). Data
were collected on age, gender, primary site and grade according to
the European Neuroendocrine Tumour Society (ENETS) guide-
lines, and presence of uptake on Gallium-68 Dotatate PET/CT or
Indium-111 pentetreotide scintigraphy. This study was approved
by the Local Ethics Committee and all participants were required
to provide written informed consent.
Immunohistochemistry. Tumours were classified according to
primary site and graded according to the ENETS guideline (Rindi
et al, 2006). Sections (3 mm) of tumour tissue were deparaffinised
in xylene and rehydrated in graded alcohols. Sections were then
placed in 0.5% hydrogen peroxidase in methanol for 10min to
block endogenous peroxidase activity. Microwave antigen retrieval
was performed for 20min in citrate buffer. Immunohistochemical
staining was carried out using the NovoLink polymer detection
system (Novocastra, Leica Microsystems, Milton Keynes, UK). A
section from each tissue specimen was incubated with either (i)
rabbit anti-SSTR2 antibody (UMB1, Abcam; ab134152) or (ii)
rabbit anti-SSTR5 antibody (UMB4, Abcam; ab109495) at a
dilution of 1 : 100 for 1 h at room temperature. Samples then
underwent post-primary block for 30min followed by NovoLink
polymer for 30min in a humidity chamber at room temperature.
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Reaction products were visualised using freshly prepared NovoLink
DAB (3,3’-diaminobenzidine tetrahydrochloride) solution for
10min by adding 50 ml of DAB chromagen to 1ml of Novolink
DAB substrate buffer. Slides were counterstained with Mayer’s
haematoxylin and mounted. Normal pancreatic tissue served as
internal positive controls. The semi-quantitative analysis of the
stained sections was performed by an independent pathologist
without any knowledge of pathological data using the DAKO
HER2/neu score (Pentheroudakis et al, 2011).
Evaluation of CTCs from NET patients. For each patient, two
7.5ml blood samples were collected into evacuated CellSave tubes
(Janssen Diagnostics, Raritan, NJ, USA) and maintained at room
temperature. All samples were processed within 96 h of collection.
The CellSearch platform was used for detection and enumeration
of CTCs as previously described (Khan et al, 2011b). Analysis of
SSTR2 and SSTR5 expression on CTCs was performed using
Alexa Fluor 488-conjugated Somatostatin Receptor 2 antibody and
Alexa Fluor 488-conjugated Somatostatin Receptor 5 antibody at
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Figure 1. CellTracks Analyzer II images. (A) SSTR transfected MCF-7-spiked blood samples. (i) SSTR2-positive tumour cell. (ii) SSTR2-negative
tumour cell. (iii) SSTR5-positive tumour cell. (iv) SSTR5-negative tumour cell. (B) Clinical validation in patient samples. (i) SSTR2-positive CTC in
patient 21. (ii) SSTR2-negative CTC in patient 21. (iii) SSTR5-positive CTC in patient 7. (iv) SSTR5-negative CTC in patient 7.
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pre-determined concentrations and exposure times. Cells were
defined as positive for SSTR2 or SSTR5 when fourth channel
staining was present. All evaluations regarding enumeration of
CTCs and expression of SSTR2 and SSTR5 were made by two
independent operators without knowledge of patient pathology.
RESULTS
Detection of SSTR expression in spiked cells. Approximately 500
SSTR2- and SSTR5-transfected MCF-7 cells were spiked separately
into 7.5ml healthy donor blood. A range of antibody concentra-
tions (SSTR2: 50 and 100 mgml 1; SSTR5; 10 mgml 1) and three
different exposure times (0.1, 0.8 and 4.0 s) were used to scan
samples using a CellSearch CTC Kit on the CellTracks Autoprep
and the Analyzer II (Figure 1A). In order to calculate optimal
antibody concentration and exposure time, SSTR2 and 5 positive
cells were enumerated and compared with expected values based
on the calculated transfection rate for that sample (SSTR2; 16%,
SSTR5; 14%) and input number of spiked cells. A scanning
exposure time of 0.8 s and antibody concentration of 50 mgml 1
for SSTR2 and 10 mgml 1 for SSTR5 was found to be optimal.
Three validation runs were subsequently performed using these
conditions and healthy donor blood. For each run, four samples
using blood from a healthy donor, and a CellSearch CTC control
sample were analysed. The four samples included: (i) healthy
donor blood alone with anti-SSTR antibody, (ii) healthy donor
blood spiked with 500 untransfected MCF-7 cells with anti-SSTR
antibody, (iii) healthy donor blood spiked with 500 transfected
MCF-7 cells with anti-SSTR antibody and (iv) healthy donor blood
spiked with 500 transfected MCF-7 cells analysed without anti-
SSTR antibody. For each run the acceptance criteria for receptor
expression were met. Of the four sample types, only the samples
spiked with transfected MCF-7 cells in the presence of anti-SSTR
antibody contained cells staining positively for SSTR2 or 5. The
number of positive cells detected for both receptors fell within the
expected range of 10–20% based on the observed transfection
efficiency for that sample.
Sensitivity of SSTR2 and 5 detection using CellSearch. Using the
CellSearch platform, cells were defined as either positive or
negative for SSTR expression according to the staining pattern
observed in the fourth channel. To investigate whether the
CellSearch was sufficiently sensitive to detect a low level of SSTR
expression, we compared the results from CellSearch directly with
flow cytometric analysis. Two separate transfections were
performed for each receptor and despite the transfection efficiency
varying between the two transfections, the overall percentage of
marker positive cells was comparable across the two different
methodologies (Table 1 and Supplementary Figure 1). These
experiments confirmed the specificity of the SSTR2 and SSTR5
antibodies and the sensitivity of the CellSearch to detect a wide
range of SSTR2 and 5 expression levels.
Effect of SA treatment on detection of SSTR2 and 5 expression
on spiked cells. As it is important clinically to be able to assess
SSTR expression in patients receiving ongoing treatment, we
evaluated the ability of our assay to detect SSTR expression in the
presence of background SA. In order to quantify this, we used
flow cytometry to measure the MFI in MCF-7 cells transfected with
SSTR2 or SSTR5 in the presence of increasing doses of lanreotide.
The mean steady-state trough serum lanreotide concentration
in patients with GEPNETs range between 5.3 and 8.6 ngml 1,
and we therefore treated our transfected cells with a range
of concentrations up to a supratherapeutic dose of 100 ngm 1
(SOMATULINEs DEPOT (lanreotide) INJECTION, 2015). The
MFI remained the same for both the SSTR2- and SSTR5-
transfected cells when treated with 0, 10 and 100 ngml 1 of
lanreotide (Table 2, Supplementary Figure 2) indicating that
detection of SSTR expression is not affected by SA therapy.
Patients for CTC evaluation. Between November 2014 and
August 2015, 32 patients with metastatic NET were recruited
from the Royal Free Hospital, London. One sample was excluded
due to a hardware malfunction during enrichment leading to
sample loss. The remaining 31 patients were included in this study
and their characteristics are shown in Table 3. Notably, the
majority of patients had midgut tumours (58%), were grade 1 or 2
Table 1. Comparison of SSTR2 and 5 detection rates using
CellSearch and FACS
Marker
Marker positive cells
detected by FACS (%)
Marker positive cells
detected by CellSearch (%)
Transfection 1a
SSTR2 37.2 36.1
SSTR5 26.7 27.7
Transfection 2
SSTR2 27.2b 22.3
SSTR5 17.6b 16.6
Abbreviation: FACS = fluorescence activated cell sorting.
aSee Supplementary Figure 1.
bAverage result over three successive runs.
Table 2. Median fluorescent intensity of SSTR-MCF-7 cells
measured by flow cytometry
Median fluorescent intensitya
Cell description
(BIM-23014)
0 ngml1
(BIM-23014)
10ngml1
(BIM-23014)
100ngml1
SSTR2-MCF-7 9463 10224 9674
SSTR5-MCF-7 14870 15184 14604
Abbreviations: MFI¼median fluorescent intensity; SA¼ somatostatin analogues. Flow
cytometry was used to quantify SSTR2 and SSTR5 expression in transfected MCF-7 cells.
MFI did not change significantly in SSTR-MCF-7 treated with SA up to a maximum
concentration of 100 ngml 1.
aAverage result over three runs.
Table 3. Clinical characteristics of NET patient samples
All patients
(n¼31)
Pancreatic
(n¼12)
Non-pancreatic
(n¼19)
Age: median (range) 62 (42–81) 56 (42–72) 64 (44–82)
Gender
Male 13 (42%) 5 (42%) 8 (42%)
Female 18 (58%) 7 (58%) 11 (58%)
Grade (ENETS)
G1 9 (29%) 3 (25%) 6 (19%)
G2 14 (45%) 5 (42%) 9 (47%)
G3 4 (13%) 3 (25%) 1 (5%)
Unknown 4 (13%) 1 (8%) 3 (16%)
Primary site
Pancreas 12 (39%) 12 (100%) –
Midgut 18 (58%) – 18 (95%)
Unknown 1 (3%) – 1 (5%)
SSTR imaging
Positive 27 (87%) 9 (75%) 18 (95%)
Negative 1 (3%) 1 (8%) –
Unknown 3 (10%) 2 (17%) 1 (5%)
SA therapy
Yes 19 (61%) 5 (42%) 14 (74%)
No 12 (39%) 7 (58%) 5 (26%)
Abbreviations: ENETS¼European Neuroendocrine Tumour Society; NET¼ neuro-
endocrine tumours; SA¼ somatostatin analogues; SSTR¼ somatostatin receptors.
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(74%) and had positive uptake on somatostatin receptor imaging
(87%). Overall, 61% were receiving therapy with SA at the time of
recruitment.
SSTR detection in CTC from metastatic NET patients. Periph-
eral blood samples from 31 patients with metastatic NET were
analysed by the CellSearch system adapted for SSTR2 and SSTR5
detection using the optimised conditions previously described. As
shown in Table 4, CTCs were detected in 21 (68%) patients
(midgut; n¼ 14, pancreatic; n¼ 6; unknown primary; n¼ 1, range;
1–636). Seven patients out of 21 (33%) showed a subpopulation of
CTCs expressing either SSTR2 (n¼ 5) or SSTR5 (n¼ 2) (Table 4
and Figure 1B). These patients had G1 or G2 tumours and no
patients with G3 tumours had SSTR(þ )CTCs. In those patients
with SSTR(þ ) CTCs, the fraction of SSTR2(þ ) or SSTR5(þ ) CTCs
varied from 10 to 100% and 50 to 100%, respectively, indicating
intra-patient heterogeneity of SSTR expression. No patients had
evidence of both SSTR2(þ )and SSTR5(þ )expression. Five out of
the seven patients with SSTR2(þ )or SSTR5(þ ) CTC subpopula-
tions were on active treatment with SA at time of sample collection,
confirming previous flow cytometry studies indicating that SA
therapy does not interfere with detection of SSTR2 or SSTR5 using
this assay.
Immunohistochemical analysis of SSTR2 and 5 expression. Of
the 21 patients with detectable CTCs, 11 had blocks of formalin-
fixed and paraffin-embedded tissue (FFPE) available for further
immunohistochemistry (IHC). Staining for SSTR2 and 5 was
predominantly membranous, although some cytoplasmic staining
was seen in occasional cases (Figure 2). Moderate to strong staining
was seen in 10 out of 11 cases for SSTR2 and only 3 out of 11 cases
for SSTR5. A further three cases showed weak staining for SSTR2
(Table 4). The concordance between the IHC and CTC staining for
SSTR 2 and 5 was variable; patients 9, 19 and 24 were positive for
SSTR2 on tissue and CTCs and patient 21 was positive for SSTR 5
on both. However, patients 7, 9,10, 25 and 27 had SSTR5
expression on tissue but not CTCs, whereas patients 5, 10, 20, 21,
25, 27 and 29 had SSTR2 expression on tissue but none in CTCs.
Conversely, patient 5 had SSTR5 expression on CTCs but not
tissue, and patient 7 had SSTR2 expression on CTCs but not tissue.
DISCUSSION
In clinical practice, expression of SSTR2 and 5 in NET patients is
measured by scintigraphy or PET imaging. However, there can be
heterogeneity in SSTR2 and 5 expression with metastatic sites
exhibiting different expression profiles when compared with the
primary tumour (Nasir et al, 2006; Hofman and Hicks, 2012;
Kaemmerer et al, 2015). Imaging lacks the resolution necessary to
visualise differences in expression profiles on a single-cell basis and
is not practical to track changes in expression over time or with
therapy. By contrast, CTCs provide a potential method to sample
the tumour tissue directly for expression relevant therapeutic
targets at a single-cell level and at multiple time points. Other
groups have previously demonstrated that targets such as HER2,
ER/PR and PD-L1 can be evaluated in CTCs and this may inform
treatment selection and stratification (Pestrin et al, 2009; Munzone
et al, 2010; Punnoose et al, 2010; Mazel et al, 2015). To our
knowledge, SSTR expression has not been evaluated previously in
CTCs and our study provides the first such analysis.
Table 4. Characteristics of patients with detectable CTCs
No. of CTCs
No. of marker positive
CTCs
Immunohistochemistry performed on
FFPE
ID Primary Site Grade SSTR imaging SA therapy Draw 1c Draw 2d SSTR2 SSTR5 SSTR2 SSTR5
1 Pancreas 2 Unknown No 34 38 0 0 ND ND
3 Unknown 3 Positivea No 95 111 0 0 ND ND
5 Midgut 1 Positivea No 0 1 0 1 2 0
6 Midgut 2 Positiveb Yes 1 0 0 0 ND ND
7 Midgut 2 Positiveb Yes 22 20 2 0 0 1
9 Pancreas 2 Positiveb No 39 20 5 0 3 3
10 Pancreas 3 Positivea No 2 2 0 0 3 3
12 Midgut 1 Positiveb Yes 9 4 1 0 ND ND
14 Midgut 1 Positivea Yes 2 0 0 0 ND ND
18 Midgut – Positiveb Yes 44 52 0 0 ND ND
19 Midgut 1 Positiveb Yes 1 2 0 2 3 0
20 Midgut 1 Positiveb Yes 2 – 0 0 2 0
21 Midgut 2 Positivea No 2 2 0 1 3 1
22 Pancreas 3 Positivea Yes 0 1 0 0 ND ND
23 Midgut 2 Positivea Yes 636 489 0 0 ND ND
24 Pancreas 1 Positiveb No 19 21 0 2 3 0
25 Midgut 1 Positivea Yes 2 2 0 0 2 1
26 Midgut – Unknown Yes 1 0 0 0 ND ND
27 Midgut 1 Positivea Yes 1 4 0 0 3 2
28 Pancreas 1 Positiveb Yes 1 7 0 0 ND ND
29 Midgut 2 Positivea Yes 2 0 0 0 2 0
Abbreviations: CTC¼ circulating tumour cells; FFPE = formalin-fixed paraffin-embedded tissue; ND¼not done; SA¼ somatostatin analogues; SSTR¼ somatostatin receptors.
aGallium-68 Dotatate PET/CT.
bIndium-111 pentetreotide scintigraphy. cDraw 1 analysed for SSTR2 expession and dDraw 2 analysed for SSTR5 expression.
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In keeping with previously published data (Khan et al, 2013a),
CTCs were isolated in 68% of metastatic NET patients overall, with
a higher proportion of midgut patients having detectable CTCs
(78%) compared with pancreatic patients (50%). In those with
detectable CTCs, we show that SSTR2 and 5 expression can be
found in a subpopulation of CTCs in 33% of patients and that
SSTR2 expression is more commonly observed than SSTR5,
consistent with the existing literature for immunohistochemistry
(de Herder et al, 2003; Reubi, 2011; Kaemmerer et al, 2012).
However, it is noteworthy that 12 of the 14 patients with no
detectable SSTR(þ ) CTC subpopulations had tumours that were
positive for SSTR expression as determined by functional imaging.
This difference is unlikely to be explained by sampling bias as large
numbers of CTCs were found in four discordant cases ranging
from 34 to 636. There was also some degree of discordance
between immunohistochemistry and CTC expression despite the
fact that the same antibody clones were used for both. For SSTR2,
there was positive expression in seven cases by IHC but not in
CTCs and for one case, there was expression in CTCs but not in
tissue. For SSTR5, there was positive expression in five cases by
IHC, which were negative in CTCs and one case where the reverse
was true. There are a number of explanations that may account for
these discrepancies. First, the expression analysis for either CTC or
IHC may not be sufficiently sensitive or specific. For CTCs, the
data from both the assay development and the fluorescence
activated cell sorting (FACS) analysis suggest that this was not the
case. The CellSearch and FACS analysis demonstrated marker
positive cells only in transfected cell populations, and the FACS
analysis showed a range of SSTR expression levels in a proportion
of cells that was equivalent to that detected by CellSearch. In
addition, the fact that some cells were clearly positive within a
population of negative cells suggests that these were truly negative.
Collectively, these findings suggest that the CellSearch assay for
SSTR2 and 5 is both sensitive and specific. Regarding IHC, other
groups have demonstrated that tissue immunoreactive scores for
SSTR2 and SSTR5 correlate with both 68-Ga DOTATOC PET/CT
and somatostatin receptor scintigraphy, and also with RT-qPCR
for SSTR2 quantification (Volante et al, 2007; Miederer et al, 2009;
Kaemmerer et al, 2011; Kaemmerer et al, 2015). Consistent with
this, all patients in our study with positive SSTR2 or 5 staining by
IHC had corresponding positive SSTR imaging suggesting that the
IHC is reliable. A second possible reason for discrepancy might be
that both imaging and histology are historical rather than
contemporaneous with respect to CTC analysis, and the reduced
SSTR expression seen in CTCs may arise from tumour evolution.
Neuroendocrine tumour patients often have an indolent disease
course resulting in an increased time between initial tumour
sampling and CTC collection. It has been reported that SSTR status
can change over the course of disease progression (Krenning et al,
2005; Gabriel et al, 2007) and in keeping with this Kaemmerer et al,
2015 have shown that SSTR2 expression as assessed by IHC is
significantly higher in pancreatic NET primary tumours than at
metastatic sites. This could lead to a positive result by IHC despite
a negative test in CTCs; the two patients (patients 5 and 7) with
complete discordance between CTC and archived tissue expression
profiles in our study had IHC performed on archived samples that
were 31 and 85 months old, respectively, and both originated from
primary tumours. However, this is unlikely to completely explain
the discordance seen, particularly given that serial imaging in most
patients demonstrate the persistence of SSTR over years. A third
and most likely explanation is that there is heterogeneity of
expression within tumours and between CTCs. Our results clearly
demonstrate heterogeneity in both tissue and CTCs, where small
subpopulations show clear expression of SSTR while the majority
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Figure 2. Immunohistochemistry for SSTR2 and SSTR5. (A) SSTR2 staining score 0. (B) SSTR2 staining score 2. (C) SSTR2 staining score 3.
(D) SSTR5 staining score 0. (E) SSTR5 staining score 2. (F) SSTR5 staining score 3.
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of cells are negative. However, as mentioned, there are four cases
with large numbers of CTCs that are all negative, whereas the
corresponding imaging is positive. These observations may reflect
the biology and/or plasticity of metastasising cells in which SSTR-
negative subpopulations are more likely to metastasise or whose
phenotype changes during translocation in the blood. It is
interesting to note that the two high-grade tumours with many
CTCs were both negative for SSTR expression.
Other groups have also reported heterogeneity or discordance
between biomarker expression on CTCs and archived tissue. For
example, several groups have investigated HER2 expression on
CTCs and archived tissue in breast cancer patients and found
discordance rates varying between 11 and 33% (Pestrin et al, 2009;
Flores et al, 2010; Munzone et al, 2010; Punnoose et al, 2010).
Concordance rates also appear to be lower when comparing CTC
biomarker expression to primary tumour samples as compared
with metastatic disease sites.
Our findings, particularly the discordance between CTC and
tissue expression, might have profound implications for therapy
and partly explain the escape from disease control seen in patients
treated with SA or peptide receptor radionuclide therapy (PRRT).
In addition, they provide intriguing insights into the phenotypic
characteristics of metastasising cells, which clearly needs further
evaluation. A key question, therefore, is the relevance of SSTR
expression on CTCs for patient management, and this is currently
being tested in the ongoing Phase IV CALM-NET study
(NCT02075606). In this multicentre prospective trial, our assay
is being used to investigate the relationship between SSTR2 and 5
expression on CTCs and progression-free survival in patients with
functioning midgut NET receiving treatment with Lanreotide
Autogel. Circulating tumour cells are being enumerated at multiple
time points during therapy and SSTR status evaluated. It is
anticipated that this longitudinal study will provide novel insights
into the role of CTCs as pharmacodynamics markers in this
disease.
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